Yu Y. Soon

378 Alexandra Road
Alexandra Estate, 159964, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression.

Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression.

Journal: Transplantation and cellular therapy

Published: April 21, 2026

A Response to the Letter to the Editor.

A Response to the Letter to the Editor.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 01, 2026

Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.

Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.

Journal: BJU international

Published: November 05, 2025

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 17, 2025

Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials.

Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: July 26, 2025

INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse.

INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse.

Journal: JNCI cancer spectrum

Published: May 04, 2025

Quality Indicators and Benchmarks for Radiotherapy in Lung Cancer: A Modified Delphi Approach.

Quality Indicators and Benchmarks for Radiotherapy in Lung Cancer: A Modified Delphi Approach.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: February 12, 2025

Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Journal: BMJ oncology

Published: January 31, 2025

Restricted mean survival time approach versus time-varying coefficient Cox model for quantifying treatment effect when hazards are non-proportional.

Restricted mean survival time approach versus time-varying coefficient Cox model for quantifying treatment effect when hazards are non-proportional.

Journal: BMC medical research methodology

Published: October 23, 2024

Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.

Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.

Journal: JAMA network open

Published: September 17, 2024

Efficacy and Safety of Four Weeks of Moderately Hypofractionated Chemoradiation for Unresectable, Stage 3 Non-Small Cell Lung Cancer: A Systematic Review.

Efficacy and Safety of Four Weeks of Moderately Hypofractionated Chemoradiation for Unresectable, Stage 3 Non-Small Cell Lung Cancer: A Systematic Review.

Journal: Asia-Pacific journal of clinical oncology

Published: August 07, 2024

Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration.

Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration.

Journal: BMJ open

Published: July 05, 2024

Showing 1-12 of 77

Last Updated: 09/26/2026